Interleukin-17A gene variants and risk of coronary artery disease: A large angiography-based study

Clinica Chimica Acta

Volumn 412, Issue 3-4, 2011, Pages 327-331

  Zhang, Xiaolin ^a   Pei, Fang ^a   Zhang, MingXiang ^b   Yan, Chenghui ^a   Huang, Mingfang ^a   Wang, Tao ^a   Han, Yaling ^a  

^a SHENYANG NORTHERN HOSPITAL   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Coronary artery disease; Inflammation; Interleukin 17A; Polymorphism

Indexed keywords

INTERLEUKIN 17;

ACUTE HEART INFARCTION; ADULT; AMINO ACID SEQUENCE; ANGIOCARDIOGRAPHY; ARTICLE; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK ASSESSMENT; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ANGIOGRAPHY; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 78650238482     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.10.027     Document Type: Article

References (31)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
2. Lindahl B., Toss H., Siegbahn A., Venge P., Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000, 343:1139-1147.
3. Frangogiannis N.G., Smith C.W., Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc Res 2002, 53:31-47.
4. Berliner J.A., Navab M., Fogelman A.M., et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995, 91:2488-2496.
5. Buja L.M., Willerson J.T. Role of inflammation in coronary plaque disruption. Circulation 1994, 89:503-505.
6. Mauriello A., Sangiorgi G., Fratoni S., et al. Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopathologic study of patients dying of acute myocardial infarction. J Am Coll Cardiol 2005, 45:1585-1593.
7. Maier W., Altwegg L.A., Corti R., et al. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation 2005, 111:1355-1361.
8. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
9. Rosenson R.S. Biomarkers, atherosclerosis and cardiovascular events. Expert Rev Cardiovasc Ther 2008, 6:619-622.
10. von der Thusen J.H., Kuiper J., van Berkel T.J., Biessen E.A. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev 2003, 55:133-166.
11. Tziakas D.N., Chalikias G.K., Tentes I.K., et al. Interleukin-8 is increased in the membrane of circulating erythrocytes in patients with acute coronary syndrome. Eur Heart J 2008, 29:2713-2722.
12. Aukrust P., Halvorsen B., Yndestad A., et al. Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol 2008, 28:1909-1919.
13. de Boer Onno J., van der Meer Jelger J., Teeling Peter, et al. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol 2010, 220:499-508.
14. Taleb S., Romain M., Ramkhelawon B., et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 2009, 206:2067-2077.
15. Eid R.E., Rao D.A., Zhou J., et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 2009, 119:1424-1432.
16. Erbel Christian, Chen Lili, Bea Florian, et al. Inhibition of IL-17A attenuates atherosclerotic lesion development in ApoE-deficient mice. J Immunol 2009, 183:8167-8175.
17. Hashmi S., Zeng Q.T. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis 2006, 17:699-706.
18. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003, 21:1011-1053.
19. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diab Care 2003, 26(Suppl 1):S5-20.
20. Deng G., Zhou G., Zhang R., et al. Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers. Gastroenterology 2008 Mar, 134(3):716-726.
21. Mio Kawaguchi, Daisuke Takahashi, Nobuyuki Hizawa, et al. IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. J Allergy Clin Immunol 2006, 117:795-801.
22. Kolls J.K., Linden A. Interleukin-17 family members and inflammation. Immunity 2004, 21:467-476.
23. Patel D.N., King C.A., Bailey S.R., et al. Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation. J Biol Chem 2007, 282:27229-27238.
24. Jovanovic D.V., Di Battista J.A., Martel-Pelletier J., et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 1998, 160:3513-3521.
25. Patel K.D., Murphy R.T., White M., et al. Interleukin 17: an unlikely marker of acute coronary syndrome?. Atherosclerosis 2009, 205:33-34.
26. Yokota M., Ichihara S., Lin T.L., Nakashima N., Yamada Y. Association of a T29>C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000, 101(24):2783-2787.
27. Koch W., Hoppmann P., Mueller J.C., Schomig A., Kastrati A. Association of transforming growth factor-beta1 gene polymorphisms with myocardial infarction in patients with angiographically proven coronary heart disease. Arterioscler Thromb Vasc Biol 2006, 26:1114-1119.
28. Koh K.K. Effects of estrogen on the vascular wall: vasomotor function and inflammation. Cardiovasc Res 2002, 55:714-726.
29. Qiu Z., Dillen C., Hu J., et al. Interleukin-17 regulates chemokine and gelatinase B expression in fibroblasts to recruit both neutrophils and monocytes. Immunobiology 2009, 214:835-842.
30. de Boer O.J., van der Meer J.J., Teeling P., et al. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol 2010, 220(4):499-508.
31. Takahashi H., Numasaki M., Lotze M.T., Sasaki H. Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Lett 2005, 98:189-193.